Market Assessment, LaunchTrends: Anoro Ellipta US Wave 3 2015 Report

LaunchTrends: Anoro Ellipta Wave 3 is the third of a three-wave report series designed to track the post-launch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment of chronic obstructive pulmonary disease (COPD) in the United States. This syndicated primary research report examines physicians’ perception at one year following the commercial availability of Anoro Ellipta. The report also investigates where Anoro Ellipta will fit into the treatment algorithm, likely patient candidates, perceived advantages and disadvantages of the product, and GlaxoSmithKline’s promotional efforts.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

LaunchTrends: Anoro Ellipta (US) (Wave 3) | 2015

Related Market Assessment Reports

Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Urticaria – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Chronic Inducible Urticaria (US) 2023

Ulcerative Colitis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Adult (US)

Asthma | Unmet Need | Severe Asthma | US/EU | 2021

Asthma – Unmet Need – Detailed, Expanded Analysis – Severe Asthma (US/EU)